A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
Inclusion Criteria:
Exclusion Criteria:
Ribeirao Preto - SP, São Paulo 14048-900, Brazil
Forlì Cesena, Emilia-Romagna 47014, Italy
Higashiibaraki, Ibaraki 311-3193, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Itabashi-ku, Tokyo 173-0015, Japan
Minato-ku, Tokyo 105-8471, Japan
Nakano-ku, Tokyo 164-8541, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Sumida-ku, Tokyo 130-8587, Japan
Leipaja, LV-3401, Latvia
George, Eastern Cape 6530, South Africa
Kaoshiung, 81362, Taiwan